61 results about "Fusobacterium" patented technology

The invention relates to one or more systems and methods for creating a mixture of cultures used to replace intestinal flora. Specifically, the invention relates to methods and systems of treating diseases including Clostridium difficile and Crohn's disease by introducing a mixture of pure cultures of viable bacteria into the gastrointestinal tract.

Certain bile acids, including novel bile acids, and derivatives thereof can be used to inhibit the germination of C. difficile spores and/or the growth of C. difficile cells. The methods and compositions of the invention are useful for preventing and treating C. difficile-associated diseases, including but not limited to C. difficile colitis.

The present invention provides a gene chip for quickly detecting pathogens from food source, discloses the preparation method of said gene chip and provides 26 oligonucleotide probe sequences for detection. Said gene chip can quickly, accurately and high-effectively detect and identify the class of the pathogens in food, and its detection range includes staphylococcus aureus, Shiga's bacillus, salmonella, colibacillus 0157, bacillus proteus, mononuclear hyperplastic listerella, enterocolitis yersinia, aeruginous pseudomonads, vibrio parahaemolyticus, vibrio cholerae, bacillus cereus, beta hemolytic streptococcus, coconut fermentation pseudomonads, boticin, vibrio jejuni and bacillus perfringens, etc.

The present invention provides for immunogenic compositions and their methods of use as vaccines and their method of preparation. These immunogenic compositions comprise a recombinant protein of toxin A or toxin B of Clostridium difficile conjugated to a polysaccharide of a microbial pathogen. The immunogenic compositions may include only a truncated portion of toxin A or toxin B, particularly the repeating units (rARU or rBRU), that is associated with a microbial pathogen polysaccharide. Such compositions are effective in eliciting T-cell dependent and antibody responses. These compositions are therefore effective as vaccines for humans, particularly children, and animals in affording protection against one or more microbial pathogens.

The C. difficile proteins Cwp84, FliC and FliD, known to have conserved peptide sequences, were separately injected into female chickens, and the antibody rich egg yolks harvested. The antibody compositions were then titered by ELISA and western immunoblotting. Anti-FliD IgY, anti-Cwp84 IgY, and an equititer cocktail of the three IgY antibodies was administered to hamsters infected with a C. difficile strain and found effective as potential treatments.

The invention relates to the fields of genetic engineering and biomedicine, and more specifically relates to a biomarker of schizophrenia and its application. The invention discloses a marker of schizophrenia and its application in preparing a kit for diagnosing schizophrenia, and also discloses a kit for detecting the marker. The schizophrenia markers disclosed in the present invention include Prevotella, Succinivibrio, Fusobacterium, Lactobacillus, and Megasphaera , Acidaminococcus, Citrobacter, Phascolarctobacterium, Coprococcus, Roseburia, Blautia 11 species At least 5 of the microorganisms. The marker provided by the invention can judge schizophrenia and normal people, the AUC is above 0.81, has good diagnostic efficiency, and can be used to prepare a kit for effectively diagnosing schizophrenia.

The invention belongs to the technical field of biomedicine, relating to a clostridium difficile exotoxin A carboxy-terminal gene sequence with optimized codon and a nucleic acid vaccine thereof. The codon optimized gene sequence gives consideration to use preferences of mammalian cells and Esherichia coli codon, and the related clostridium difficile vaccine is composed of exotoxin A carboxy-terminal gene sequence with optimized codon and eukaryon expression vector pJW4303. The clostridium difficile exotoxin A carboxy-terminal gene segment optimized by codon can not only be used for constructing nucleic acid vaccines, effectively stimulating host immune system after immunizing mammals, generating better humoral immunity reaction, being applicable to conduct pronucleus expression in esherichia coli, and laying a foundation for acquiring protein in great quantities.

The invention relates to compositions and methods to prevent enteric infection in a subject at risk of such infection. In particular, the invention relates to the prevention of recurrence of infection by Clostridium difficile.

The invention provides a fusobacterium nucleatum polymorphic subspecies isolate THCT15E1, a classification name is Fusobacterium nuucleates subsp.nucleatum THCT15E1, a preservation number of the strain is CCTCC NO: M 2019362, a preservation date is May 17, 2019, a preservation unit is China Center for Type Culture Collection, and the 16SrRNA gene sequence of the strain is shown as SEQ ID NO: 1. The result of co-culture of the colorectal cancer cell line and THCT15E1 shows that THCT15E1 can significantly promote colorectal cancer cell proliferation; therefore, the THCT15E1 can provide diversified experimental conditions for in-vitro or in-vivo intestinal environment simulation for colorectal cancer research, and can also construct a colorectal cancer disease model to screen drugs for treating colorectal cancer.

The invention discloses mouthwash capable of effectively inhibiting bacteria and a preparation method thereof. The mouthwash is composed of an antibacterial biological extract, sodium bicarbonate, biologically refined glycerin, peppermint oil, lauryl sodium sulfate, a freshener WS-23, an anti-caking agent, a sweetening agent and a mouthwash matrix. Wherein the antibacterial biological extract is natamycin, nisin and phenyllactic acid; natamycin, nisin and phenyllactic acid are weighed, natamycin, nisin and phenyllactic acid are added into purified water, stirring is carried out through a reaction kettle until natamycin, nisin and phenyllactic acid are dissolved, and other components can be added, stirring at a high speed is carried out until all substances are dissolved, and finally packaging is carried out after sterile filling. The mouthwash disclosed by the invention contains natamycin, nisin and phenyllactic acid, the mouthwash can effectively kill and inhibit G<+> and G<->bacteriasuch as porphyromonas gingivalis, actinobacillus actinomycetemcomitan, Fusobacterium, streptococcus mutans and the like in the oral cavity, has a decomposition effect on plaque biofilms generated byflora, can decompose dental plaque while protecting beneficial bacteria, and has the tooth cleaning effect while sterilizing and removing the plaque.

The invention provides a crystal form of (s)-ornidazole phosphate disodium, and a preparation method for the crystal form of the (s)-ornidazole phosphate disodium. In addition, pharmaceutical compositions containing the crystal form of the (s)-ornidazole phosphate disodium are applied in treatment of a plurality of infectious diseases caused by sensitive anaerobic bacteria like bacteroides fragilis, bacteroides distasonis, bacteroides ovatus, bacteroides thetaiotaomicron, bacteroides vulgatus, clostridium colinum, eubacterium, peptococcus and peptostreptococcus, helicobacter pylori, bacteroides melaninogenicus, fusobacterium, capnocytophaga and bacteroides gingivalis.

The invention relates to a preparation containing Fusobacterium nucleatum and PD-L1 antibody and used for immunotherapy of colorectal cancer, application of the preparation, a Fusobacterium nucleatummarker to predict curative effect of PD-L1 antibody therapy of colorectal cancer, and application of the marker. The influence of Fusobacterium nucleatum upon PD-L1 antibody immunotherapy of colorectal cancer is studied deeply herein, and it is discovered that PD-L1 monoclonal antibody therapy is more effective to colorectal cancer in the presence of Fusobacterium nucleatum, while PD-L1 monoclonalantibody therapy helps evidently extend the lifetime of a mouse with colorectal cancer in the presence of Fusobacterium nucleatum; by discussing the mechanism of Fusobacterium nucleatum, it is discovered that Fusobacterium nucleatum can provide transcriptional control for the expression of PD-L1; after PD-L1 antibody therapy is carried out for colorectal cancer tissues in the presence of Fusobacterium nucleatum, the proportion of CD8 positive T cells is increased; all these above are good for the effect of PD-L1 antibody therapy. It is indicated that the presence or absence of Fusobacterium nucleatum is suitable for acting as a potential marker to judge the curative effect of PD-L1 monoclonal antibody therapy for the patient with colorectal cancer; Fusobacterium nucleatum and PD-L1 monoclonal antibody can form an immunotherapy preparation for patients with colorectal cancer.

The invention discloses a kit for identifying colorectal cancer. The kit is characterized by comprising a specific primer combination for identifying indicating bacteria, wherein the primer combination is shown as SEQ ID NO.1-12, and the indicating bacteria are a combination of F. nucleatum, P. anaerobius, C. symbiosum, E. faecalis, P. asaccharolytica and S. salivaricus. The invention also discloses an application of the kit. The kit has the beneficial effects that risk prediction of colorectal cancer can be carried out only by collecting stool samples. The principle is to detect colorectal cancer pathogenic bacteria in feces, wherein the risk assessment sensitivity can reach 92% and the specificity is 95%.

The present invention relates to an antibody having specificity for an immunogenic determinant consisting of the pentasaccharide repeating unit of the Clostridium difficile glycopolymer PS-I: α-L-Rhap-(1→3)-β-D-Glcp-(1→4)-[α-L-Rhap-(1→3)]-α-D-Glcp-(1→2)-α-D-Glcp or a fragment thereof. Said antibody is able to prevent and treat diseases caused by C. difficile. The present invention further pertains to a method of treating or preventing a disease caused by the pathogen Clostridium difficile, which comprises administering to a subject said antibody or a vaccine composition comprising said antibody.

The invention relates to a colorectal cancer biomarker as well as a screening method and application thereof, and belongs to the technical field of cancer diagnosis. The colorectal cancer biomarker provided by the invention comprises human intestinal microorganisms and/or fecal human target genes; the intestinal microorganisms of the human body comprise one or more than two of Brawtella, Pseudomonas 9, Fecal bacillus, fusiform, Wehonor coccus, Escherichia coli-Shigella, Mycobacterium, Fusobacterium, Porphyrinium, peptostreptococcus and Bacteroides; the fecal human body target spot gene comprises ADHFE1 and/or SDC2. The biomarker combination disclosed by the invention is high in sensitivity and good in specificity, and has a profound prospect for estimating the risk of colorectal cancer. According to the invention, a data model is established through the biomarker, and the model can be used for evaluating the risk of colorectal cancer.

The invention discloses a microelement selenium dietary supplement with a function of regulating intestinal flora and an application thereof and belongs to the technical field of food. According to the invention, when the dosage of the microelement selenium dietary supplement reaches up to the level of a selenium-rich group and a high-selenium group, the intestinal microorganisms in the body can be obviously improved and the relative abundance of probiotics, such as lactobacillus and bifidobacterium, can be obviously promoted, and the relative abundance of pathogenic bacteria, such as enterobacteriaceae and fusobacterium, can be obviously reduced. The microelement selenium dietary supplement can effectively promote the antioxidant ability of the body and has a wide application prospect.